Overview

This trial is active, not recruiting.

Condition heart failure
Treatments anakinra (weeks 1-2), anakinra (weeks 3-12), placebo
Phase phase 2/phase 3
Sponsor Virginia Commonwealth University
Collaborator National Heart, Lung, and Blood Institute (NHLBI)
Start date February 2014
End date September 2016
Trial size 60 participants
Trial identifier NCT01936909, 1R34HL117026, RED-HART (HM15339)

Summary

The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
anakinra (weeks 1-2)
Anakinra 100 mg daily for weeks 1 and 2
(Experimental)
Anakinra 100 mg daily for 12 weeks
anakinra (weeks 1-2)
Anakinra 100 mg daily for weeks 1 and 2
anakinra (weeks 3-12) Anakinra 100 mg daily for weeks 3 through 12
(Placebo Comparator)
Placebo injections daily for 12 weeks
placebo Placebo daily for week 1 through 12

Primary Outcomes

Measure
Placebo-corrected interval changes in peak oxygen consumption (VO2) and ventilatory efficiency (VE/VCO2 slope)
time frame: 2 weeks

Secondary Outcomes

Measure
Quality of life improvement
time frame: 12 weeks
Survival free of hospital admission
time frame: 12 weeks

Eligibility Criteria

Male or female participants from 21 years up to 130 years old.

Inclusion Criteria: All 6 criteria need to be met for enrollment of the patient in the study 1. Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below: 1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion; 2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met); - pulmonary congestion/edema at physical exam OR chest X-Ray; - plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml; - invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg. 2. The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction <50%) at most recent assessment by any imaging modality (within 12 months). 3. The patient is now clinically stable and meets standard criteria for hospital discharge as documented by all the 3 conditions listed below: 1. absence of dyspnea or pulmonary congestion/distress at rest; 2. absence of pitting edema in the lower extremities, or in any other region; 3. stable hemodynamic parameters (blood pressure, heart rate). 4. The patient is of age ≥21 years old, and is willing and able to provide written informed consent. 5. The patient is willing and able to comply with the protocol (i.e. self administration of the treatment, and exercise protocol). 6. The patient has screening plasma C-reactive protein levels >2 mg/L. Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria. 1. The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias. 2. Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration. 3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries. 4. Previous or planned implantation of left ventricular assist devices or heart-transplant. 5. Chronic use of intravenous inotropes. 6. Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]). 7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus). 8. Active infection (of any type); 9. Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS). 10. Prior (within the past 10 years) or current malignancy. 11. Any comorbidity limiting survival or ability to complete the study. 12. End stage kidney disease requiring renal replacement therapy. 13. Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3). 14. Pregnancy. 15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.

Additional Information

Official title Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study
Principal investigator Antonio Abbate, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Virginia Commonwealth University.